Anthem Biosciences, a CRDMO, is set to launch an IPO to raise ₹3,395 crore, diluting the promoter group's stake. While revenue and profit have increased, the company faces geographical and client concentration risks. Despite a high P/E ratio compared to peers, investors with a high-risk (...)
Site référencé: The Economic Times
The Economic Times
Time to book profits ? Anand James recommends sell on rise strategy for IT stocks
13/07/2025
HCL Tech Q1 preview : Street expects muted sequential show amid seasonal softness. 5 key things to check
13/07/2025
Q1 earnings : Motilal Oswal picks ICICI Bank among 22 stocks as top bets across large, mid, smallcaps
13/07/2025
Jane St impact : Are mysterious price moves in Nifty 50 options sign of market manipulation ?
13/07/2025
FPI outflows at Rs 1 lakh crore in 2025 so far ; Rs 555 crore pulled out in July alone
12/07/2025
NSE, NSDL shares slide up to 21% from peaks. What’s behind the selling pressure in unlisted market ?
12/07/2025
